PERIPHERAL T CELLS LYMPHOMA (PTCL)
Clinical trials for PERIPHERAL T CELLS LYMPHOMA (PTCL) explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELLS LYMPHOMA (PTCL) trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELLS LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Matched conditions: PERIPHERAL T CELLS LYMPHOMA (PTCL)
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising new combo offers hope for aggressive lymphoma that stopped responding to treatment
Disease control Recruiting nowThis study tests a combination of three drugs (zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome) in about 26 adults with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this mix can shrink tumors and help…
Matched conditions: PERIPHERAL T CELLS LYMPHOMA (PTCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC